EquityFlow
›
Companies
› Blue Earth Therapeutics
Blue Earth Therapeutics
biotech
· Oxford, GB
PSMA-targeted radioligand therapies for prostate cancer.
Funding history
Date
Round
Amount
Nov 2024
Series A
Blue Earth Therapeutics raised a USD 76.5M Series A led by Soleus Capital and Sands Capital for its prostate-cancer radioligand therapies.
$76.5M
Investors
Sands Capital
Soleus Capital
Similar companies in biotech
Antag Therapeutics
Adcendo
Freya Biosciences
TXN Systems
Promise Bio
Concinnity Genetics
Noema Pharma
MabGenesis
RadioNano Therapeutics
Citryll
Alveron Pharma
AQEMIA
Explore funding flow on EquityFlow →